反对意见还是志同道合？国际工作组和阿尔茨海默病协会的标准

IF 11.7 1区医学 Q1 CLINICAL NEUROLOGY

Brain Pub Date : 2025-10-01 DOI:10.1093/brain/awaf366

Inge M W Verberk, Argonde C van Harten, Wiesje M van der Flier

{"title":"反对意见还是志同道合？国际工作组和阿尔茨海默病协会的标准","authors":"Inge M W Verberk, Argonde C van Harten, Wiesje M van der Flier","doi":"10.1093/brain/awaf366","DOIUrl":null,"url":null,"abstract":"The 2024 AA and IWG diagnostic criteria for Alzheimer’s disease differ in their classification of asymptomatic individuals. Verberk et al. argue, however, that their shared requirement for biomarker use in diagnosis means they are now largely aligned, marking a pivotal step towards precision medicine in dementia care.","PeriodicalId":9063,"journal":{"name":"Brain","volume":"72 1","pages":""},"PeriodicalIF":11.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria\",\"authors\":\"Inge M W Verberk, Argonde C van Harten, Wiesje M van der Flier\",\"doi\":\"10.1093/brain/awaf366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 2024 AA and IWG diagnostic criteria for Alzheimer’s disease differ in their classification of asymptomatic individuals. Verberk et al. argue, however, that their shared requirement for biomarker use in diagnosis means they are now largely aligned, marking a pivotal step towards precision medicine in dementia care.\",\"PeriodicalId\":9063,\"journal\":{\"name\":\"Brain\",\"volume\":\"72 1\",\"pages\":\"\"},\"PeriodicalIF\":11.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/brain/awaf366\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/brain/awaf366","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

阿尔茨海默病的2024 AA和IWG诊断标准在对无症状个体的分类上有所不同。然而，Verberk等人认为，他们在诊断中使用生物标志物的共同要求意味着他们现在在很大程度上是一致的，这标志着痴呆症护理中精准医学的关键一步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria

The 2024 AA and IWG diagnostic criteria for Alzheimer’s disease differ in their classification of asymptomatic individuals. Verberk et al. argue, however, that their shared requirement for biomarker use in diagnosis means they are now largely aligned, marking a pivotal step towards precision medicine in dementia care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brain 医学-临床神经学

CiteScore

20.30

自引率

4.10%

发文量

458

审稿时长

3-6 weeks

期刊介绍： Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.